Prof Eberhard Grube (HELIOS Hospital Siegburg, Bonn, DE) discusses the FORWARD PRO study - 30-day outcomes following TAVI with a supra-annular self-expanding valve with pericardial wrap.
Filmed on site at EuroPCR 2019 by Radcliffe Cardiology
1. Can you describe the valve used in FORWARD PRO and why this study is needed?
2. What is the study design and associated endpoints?
3. What were your findings?
4. What does this mean for practice?
5. How long will patients be followed as part of this study?
Videography: Mike Knight
Interviewer: Liam O'Neill